Abstract
Background SARS-CoV-2 has drastically affected healthcare globally and causes COVID-19, a disease that is associated with substantial morbidity and mortality. We aim to describe rates and pathogens involved in co-infection or subsequent infections and their impact on clinical outcomes among hospitalized patients with COVID-19.
Methods Incidence of and pathogens associated with co-infections, or subsequent infections, were analyzed in a multicenter observational cohort. Clinical outcomes were compared between patients with a bacterial respiratory co-infection (BRC) and those without. A multivariable Cox regression analysis was performed evaluating survival.
Results A total of 289 patients were included, 48 (16.6%) had any co-infection and 25 (8.7%) had a BRC. No significant differences in comorbidities were observed between patients with co-infection and those without. Compared to those without, patients with a BRC had significantly higher white blood cell counts, lactate dehydrogenase, C-reactive protein, procalcitonin and interleukin-6 levels. ICU admission (84.0 vs 31.8%), mechanical ventilation (72.0 vs 23.9%) and in-hospital mortality (45.0 vs 9.8%) were more common in patients with BRC compared to those without a co-infection. In Cox proportional hazards regression, following adjustment for age, ICU admission, mechanical ventilation, corticosteroid administration, and pre-existing comorbidities, patients with BRC had an increased risk for in-hospital mortality (adjusted HR, 3.37; 95% CI, 1.39 to 8.16; P = 0.007). Subsequent infections were uncommon, with 21 infections occurring in 16 (5.5%) patients.
Conclusions Co-infections are uncommon among hospitalized patients with COVID-19, however, when BRC occurs it is associated with worse clinical outcomes including higher mortality.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; MPC has received honorariums from Nabriva Therapeutics, Theravance Biopharma, Inc., Paratek Pharmaceuticals, and bioMerieux, Inc., outside the submitted work; EAD reports being a sub-investigator for clinical trials through Gilead, research funding from Nektar, personal fees for delivering educational presentations for Sanofi-Pasteur, and has received honorariums from Cumberland Pharmaceuticals and Tetraphase Pharmaceuticals, outside the submitted work; no other authors report relationships or activities that could appear to have influenced the submitted work.
Funding Statement
No support from any organization for the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Aspire institutional review board approved this multicenter observational cohort study as minimal-risk research using data collected for routine clinical practice and waived the requirement for informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; MPC has received honorariums from Nabriva Therapeutics, Theravance Biopharma, Inc., Paratek Pharmaceuticals, and bioMerieux, Inc., outside the submitted work; EAD reports being a sub-investigator for clinical trials through Gilead, research funding from Nektar, personal fees for delivering educational presentations for Sanofi-Pasteur, and has received honorariums from Cumberland Pharmaceuticals and Tetraphase Pharmaceuticals, outside the submitted work; no other authors report relationships or activities that could appear to have influenced the submitted work.
Data Availability
All data collected for the referenced study is maintained and available for the next 7 years by the authors.
